PCM
DNA icon

Pathway Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Pathway Capital Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-36,735
Closed -$5.92M – 6
2022
Q1 		$5.92M Buy
+36,735
New +$7.15M 31.56% 2

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pathway Capital Management's DNA Position: Q2 2022 in Review

Pathway Capital Management sold out of Ginkgo Bioworks (DNA) in Q2 2022, closing a stake of 36,735 shares — an estimated $5.92M sold.

Pathway Capital Management first reported a position in DNA in Q1 2022 and held it in 1 quarter. The position peaked at $5.92M in Q1 2022. 260 funds tracked by Wall St. Rank hold DNA as of Q2 2022.

  • Pathway Capital Management reported no remaining Ginkgo Bioworks position as of Q2 2022 after selling out during the quarter.
  • Pathway Capital Management sold 36,735 Ginkgo Bioworks shares in Q2 2022, an estimated $5.92M.
  • Pathway Capital Management first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 1 quarter.
  • Pathway Capital Management's Ginkgo Bioworks position peaked at $5.92M in Q1 2022.
  • 260 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2022.

Based on Pathway Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.